Börsveckan analyzes the eight companies in the Easter edition of the newspaper, but it becomes clear just buying advice for RNB and Svedberg’s and sell recommendations for Stille. The other five companies fall into the neutral category. In addition, on no changes in the portfolio.
Plastic Component manufacturer Nolato delivers record-strong results on assembly lines and the share has risen to more than 200 crowns. Börsveckan see in the short term no greater potential in the shares, but for the långsiktige’s shares are still worth buying.
The view of the clothing giant H & amp; M’s shares have gone sour precariously in recent times when the strong US dollar is expected to push the gross margin. Now the question is about expansion and growth in the top line can compensate for lower profitability. The newspaper believes that the stock is fully valued and choosing to wait.
H & amp; M’s Spanish rival Inditex has after a few sluggish years got up the pace. The company bills this year, up a step, while profitability is a positive trend. This also applies aktiekursen.Börsveckan think that the H & amp; M is the better choice of the two global clothing giants.
Bathroom manufacturer Svedberg had struggled ever since the financial crisis of falling demand and price pressure. Now, however, it seems to have turned to the venerable company. Unfortunately, the share price no greater potential. The magazine believes in a calmer course journey ahead, and will wait shares.
Clothing Company RNB after several tough years finally some tailwind in the sails. The latest report was strong and showed rising sales and profits in all business areas. The definitive turnaround may take some time, but willing to take risk, it may be time to buy now, think Börsveckan and provide buying advice.
Micro Systemation has made a hefty boost in both growth and profitability. It is mainly in North America that is growing and the question is how much the company bothered to grow this year. The newspaper believes that the shares are reasonably valued and choosing to wait.
The medical technology company Stille has never earned any money to speak of. The stock has evolved then the last ten years. This year, the stock has risen by 25 percent, slightly Börsveckan not believe is justified. The newspaper believes that the company is overvalued and emphasizes that the CEO and management own few shares. Stille’s still a sales candidate, reads the recommendation.
Studsvik looks to be on track and management expects increased growth and profitability going forward. However the market is skeptical and value shares to the p / e 10, based on this year’s expected earnings. Börsveckan are more optimistic and provide buying advice for shares, but stresses that it is always great uncertainty about earnings forecasts for Studsvik.
No comments:
Post a Comment